Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Abstract Objectives Crizotinib has demonstrated good efficacy in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). Continuing crizotinib therapy beyond progressive disease (CBPD) can achieve ongoing survival benefit in real‐world clinical practice. In terms...

Полное описание

Библиографические подробности
Главные авторы:	Guangjian Yang, Di Ma, Haiyan Xu, Lu Yang, Junling Li, Puyuan Xing, Xuezhi Hao, Yan Wang
Формат:	Статья
Язык:	English
Опубликовано:	Wiley 2019-10-01
Серии:	Cancer Medicine
Предметы:	anaplastic lymphoma kinase inhibitor crizotinib crizotinib continuation beyond progressive disease non‐small cell lung cancer treatment duration
Online-ссылка:	https://doi.org/10.1002/cam4.2420

Схожие документы

Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib
по: Carolina Valeria Mahuad, и др.
Опубликовано: (2016-06-01)

Clinical Efficacy of Crizotinib in Treatment of Patients with Advanced NSCLC
по: Emei GAO, и др.
Опубликовано: (2016-03-01)

The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report
по: Ahmed Badran, и др.
Опубликовано: (2023-08-01)

Treatment of Patients with ALK Gene Rearranged Non-small Cell Lung Cancer  after Resistance to Crizotinib
по: Tao JIANG, и др.
Опубликовано: (2015-02-01)

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
по: Moushumi Suryavanshi, и др.
Опубликовано: (2017-01-01)

Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase‐positive non–small cell lung cancer
по: Xiya Ma, и др.
Опубликовано: (2022-06-01)

Crizotinib in treatment of lung cancer
по: Arpita Singh, и др.
Опубликовано: (2017-01-01)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
по: Dennis Christoph Harrer, и др.
Опубликовано: (2020-10-01)

Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer
по: Yuka Kuriyama, и др.
Опубликовано: (2013-08-01)

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
по: Caiyu Lin, и др.
Опубликовано: (2021-12-01)

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center
по: Chang Liu, и др.
Опубликовано: (2019-10-01)

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
по: Chan-Young Ock, и др.
Опубликовано: (2019-09-01)

The Dual Role of Autophagy in Crizotinib-Treated ALK<sup>+</sup> ALCL: From the Lymphoma Cells Drug Resistance to Their Demise
по: Estelle Espinos, и др.
Опубликовано: (2021-09-01)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
по: Muhammad Wasi Alam, и др.
Опубликовано: (2019-07-01)

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China
по: Zihua Zou, и др.
Опубликовано: (2022-01-01)

Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report
по: Henan BAI, и др.
Опубликовано: (2021-08-01)

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial
по: Daijiro Harada, и др.
Опубликовано: (2021-03-01)

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
по: Scott N. Gettinger, MD, и др.
Опубликовано: (2022-09-01)

Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea
по: Da Som Jeon, и др.
Опубликовано: (2024-02-01)

Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
по: Tomonobu Koizumi, и др.
Опубликовано: (2016-04-01)

Crizotinib-Associated Renal Cysts: A Case Series
по: Garima Suman, и др.
Опубликовано: (2019-07-01)

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
по: Woo Kyung Ryu, и др.
Опубликовано: (2022-10-01)

A Case of Orbital Metastasis as Disease Progression of Anaplastic Lymphoma Kinase-Positive Lung Cancer Treated with Crizotinib
по: Yoshihiko Sakata, и др.
Опубликовано: (2015-01-01)

Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer
по: Mohieldin A, и др.
Опубликовано: (2018-11-01)

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
по: Di Marino P, и др.
Опубликовано: (2020-03-01)

Molecular epidemiological study of microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene using immunohistochemistry as a cost effective alternative to fluorescence in situ hybridization for Indian patients with adenocarcinoma lung
по: Anurag Mehta, и др.
Опубликовано: (2017-01-01)

Clinical characteristics and risk factors of drug‐induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis
по: Ken Koshikawa, и др.
Опубликовано: (2020-06-01)

Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report
по: Jun Osugi, и др.
Опубликовано: (2016-01-01)

Clinical Efficacy of Crizotinib in Advanced ALK Positive  Non-small Cell Lung Cancer
по: Jing ZHAO, и др.
Опубликовано: (2015-10-01)

Modern treatment of ALK-positive non-small cell lung cancer
по: D. A. Kharagezov, и др.
Опубликовано: (2022-06-01)

Identification of a novel ALK variant intrinsically resistant to crizotinib
по: Ullas Batra, и др.
Опубликовано: (2020-12-01)

Efficacy and Safety of Crizotinib in Advanced or Recurrent  ALK-positive Non-small Cell Lung Cancer
по: Xiaoyan LI, и др.
Опубликовано: (2019-08-01)

Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature
по: Peng Zhang, и др.
Опубликовано: (2024-04-01)

Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL
по: Wanying Liu, и др.
Опубликовано: (2024-02-01)

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
по: Yurong Wang, и др.
Опубликовано: (2022-12-01)

Long‐term response to crizotinib in a 17‐year‐old boy with treatment‐naïve ALK‐positive non‐small‐cell lung cancer
по: Giacomina Megaro, и др.
Опубликовано: (2022-03-01)

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study
по: Caicun Zhou, MD, PhD, и др.
Опубликовано: (2024-09-01)

Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib
по: Yuhang Zhou, и др.
Опубликовано: (2023-11-01)

Efficacy of crizotinib therapy for a patient with non-small cell lung cancer with ALK gene rearrangement – case report and review of current therapeutic options
по: Julia Barbara Bargieł, и др.
Опубликовано: (2021-09-01)

A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib
по: Min Zhang, MBBS, и др.
Опубликовано: (2021-02-01)